PRODUCT INFORMATION

ML-218

Item No. 43541

CAS Registry No.:	1346233-68-8
Formal Name:	3,5-dichloro-N-[[(1α,5α,6α)-3-(3,3-dimethylbutyl)-3-azabicyclo[3.1.0]hex-6-yl]methyl]-benzamide
MF:	$C_{19}H_{26}Cl_2N_2O$
FW:	369.3
Purity:	≥98%
Supplied as:	A solid
Storage:	-20°C
Stability:	≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ML-218 is supplied as a solid. A stock solution may be made by dissolving the ML-218 in the solvent of choice, which should be purged with an inert gas. ML-218 is sparingly soluble (1-10 mg/ml) in ethanol and slightly soluble (0.1-1 mg/ml) in DMSO.

Description

ML-218 is an inhibitor of T-type voltage-gated calcium channel 3.2 ($Ca_v3.2$) and $Ca_v3.3$.[1] It inhibits currents in whole-cell patch clamp assays using HEK293 cells expressing $Ca_v3.2$ or $Ca_v3.3$ (IC_{50}s = 310 and 274 nM, respectively). ML-218 (0.1-30 mg/kg) decreases the latency to paw withdrawal in a rat model of catalepsy induced by haloperidol (Item No. 12014).

Reference

1. Xiang, Z., Thompson, A.D., Brogan, J.T., *et al.* The discovery and characterization of ML218: A novel, centrally active T-type calcium channel inhibitor with robust effects in STN neurons and in a rodent model of Parkinson's Disease. *ACS Chem. Neurosci.* **2(12)**, 730-742 (2011).

CAYMAN CHEMICAL
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
PHONE: [800] 364-9897
[734] 971-3335
FAX: [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM